Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program

VIENNA, Austria, March 18, 2026 /PRNewswire/ -- Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced an exclusive global license agreement with Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) for technology related to Valneva's Clostridioides difficile vaccine candidate, VLA84. Under the agreement, Elaris obtains an exclusive global license to Valneva's antigen technology targeting Clostridioides difficile.